Baxter International Inc. (NYSE:BAX – Get Free Report) has been given a consensus rating of “Hold” by the nine research firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $39.44.
A number of analysts have recently issued reports on BAX shares. StockNews.com lowered Baxter International from a “buy” rating to a “hold” rating in a report on Monday, November 11th. Stifel Nicolaus decreased their price objective on Baxter International from $46.00 to $38.00 and set a “buy” rating for the company in a research report on Monday, November 11th. Finally, Citigroup lowered their target price on Baxter International from $37.00 to $35.00 and set a “neutral” rating on the stock in a research note on Wednesday, December 11th.
Read Our Latest Analysis on BAX
Institutional Investors Weigh In On Baxter International
Baxter International Stock Down 0.7 %
Shares of NYSE:BAX opened at $30.61 on Friday. The firm has a 50 day simple moving average of $30.70 and a 200 day simple moving average of $34.38. Baxter International has a 52 week low of $28.33 and a 52 week high of $44.01. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.09 and a current ratio of 1.43. The company has a market cap of $15.63 billion, a PE ratio of 153.03, a price-to-earnings-growth ratio of 9.83 and a beta of 0.61.
Baxter International Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 1st. Investors of record on Friday, February 28th will be issued a $0.17 dividend. This represents a $0.68 annualized dividend and a yield of 2.22%. Baxter International’s dividend payout ratio (DPR) is presently 340.02%.
About Baxter International
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.
Further Reading
- Five stocks we like better than Baxter International
- Market Cap Calculator: How to Calculate Market Cap
- META Stock: Insider Selling Ramps Up—What It Means for Investors
- The Risks of Owning Bonds
- 3 Chip Stocks Still Trading 50% Below Their 52-Week Highs
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- U.S. Steel: Will Trump-Backed Nippon Investment Drive Upside?
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.